Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide

Abstract

The transcription factor nuclear factor-κB (NF-κB) regulates genes important for tumor invasion, metastasis and chemoresistance. Normally, NF-κB remains sequestered in an inactive state by cytoplasmic inhibitor-of-κB (IκB) proteins. NF-κB translocates to nucleus and activates gene expression upon exposure of cells to growth factors and cytokines. We and others have shown previously that NF-κB is constitutively active in a subset of breast cancers. In this study, we show that constitutive activation of NF-κB leads to overexpression of the anti-apoptotic genes c-inhibitor of apoptosis 2 (c-IAP2) and manganese superoxide dismutase (Mn-SOD) in breast cancer cells. Furthermore, expression of the anti-apoptotic tumor necrosis factor receptor associated factor 1 (TRAF1) and defender-against cell death (DAD-1) is regulated by NF-κB in certain breast cancer cells. We also demonstrate that NF-κB-inducible genes protect cancer cells against paclitaxel as MDA-MB-231 breast cancer cells modified to overexpress IκBα required lower concentrations of paclitaxel to arrest at the G2/M phase of the cell cycle and undergo apoptosis when compared to parental cells. The effect of NF-κB on paclitaxel-sensitivity appears to be specific to cancer cells because normal fibroblasts derived from embryos lacking p65 subunit of NF-κB and wild type littermate embryos were insensitive to paclitaxel-induced G2/M cell cycle arrest. Parthenolide, an active ingredient of herbal remedies such as feverfew (tanacetum parthenium), mimicked the effects of IκBα by inhibiting NF-κB DNA binding activity and Mn-SOD expression, and increasing paclitaxel-induced apoptosis of breast cancer cells. These results suggest that active ingredients of herbs with anti-inflammatory properties may be useful in increasing the sensitivity of cancers with constitutively active NF-κB to chemotherapeutic drugs.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Amato SF, Swart JM, Berg M, Wanebo HJ, Mehta SR and Chiles TC. . 1998 Cancer Res. 58: 241–247.

  • Ambrosone CB, Freudenheim JL, Thompson PA, Bowman E, Vena JE, Marshall JR, Graham S, Laughlin R, Nemoto T and Shields PG. . 1999 Cancer Res. 59: 602–606.

  • Baeuerle PA and Henkel T. . 1994 Annu. Rev. Immunol. 12: 141–179.

  • Baldini N. . 1997 Nat. Med. 3: 378–380.

  • Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C and Dorken B. . 1997 J. Clin. Invest. 100: 2961–2969.

  • Bargou RC, Wagener C, Bommert K, Mapara MY, Daniel PT, Arnold W, Dietel M, Guski H, Feller A, Royer HD and Dörken B. . 1996 J. Clin. Invest. 97: 2651–2659.

  • Beg AA and Baltimore D. . 1996 Science 274: 782–784.

  • Bentires-Aji M, Hellin A-C, Ameyar M, Chouaib S, Merville M-P and Bours V. . 1999 Cancer Res. 59: 811–815.

  • Berenbaum KC. . 1981 Adv. Cancer Res. 25: 269–335.

  • Bhat-Nakshatri P, Newton TR, Goulet Jr R and Nakshatri H. . 1998 Proc. Natl Acad. Sci. USA 95: 6971–6976.

  • Biswas DK, Dezube BJ, Ahlers CM and Pardee AB. . 1993 J. Acquir. Immune Defic. Syndr. 6: 778–786.

  • Blagosklonny MV, Schulte T, Nguyen P, Trepel J and Neckers LM. . 1996 Cancer Res. 56: 1851–1854.

  • Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J and Neckers L. . 1995 Cancer Res. 55: 4623–4626.

  • Bork PM, Schmitz ML, Kuhnt M, Escher C and Heinrich M. . 1997 FEBS Lett 402: 85–90.

  • Cassimeris L. . 1999 Curr. Opin. Cell Biol. 11: 134–141.

  • Cogswell PC, Guttridge DC, Funkhouser WK and Baldwin Jr AS. . 2000 Oncogene 19: 1123–1131.

  • Das KC and White CW. . 1997 J. Biol. Chem. 272: 14914–14920.

  • Deveraux QL and Reed JC. . 1999 Genes Dev. 13: 239–252.

  • Dignam JD, Lebovitz RM and Roeder RG. . 1983 Nucleic Acids Res. 11: 1475–1489.

  • Dong G, Chen Z, Kato T and Van Waes C. . 1999 Cancer Res. 59: 3495–3504.

  • Ferlini C, Scambia G, Distefano M, Filippini P, Isola G, Riva A, Bombardelli E, Fattorossi A, Benedetti Panici P and Mancuso S. . 1997 Br. J. Cancer 75: 884–891.

  • Fisher DE. . 1994 Cell 78: 539–542.

  • Fukuda K, Hibiya Y, Mutoh M, Koshiji M, Akao S and Fujiwara H. . 1999 Planta Med. 65: 381–383.

  • Galien R and Garcia T. . 1997 Nucleic Acids Res. 25: 2424–2429.

  • Giri DK and Aggarwal BB. . 1998 J. Biol. Chem. 273: 14008–14014.

  • Green DR and Reed JC. . 1998 Science 281: 1309–1312.

  • Grumont RJ, Rourke IJ and Gerondakis S. . 1999 Genes Dev. 13: 400–411.

  • Gutman A and Wasylyk B. . 1990 EMBO J. 9: 2241–2246.

  • Guttridge DC, Albanese C, Reuther JY, Pestell RG and Baldwin Jr AS. . 1999 Mol. Cell. Biol. 19: 5785–5799.

  • Habtemariam S. . 1998 Planta Med. 64: 683–685.

  • Hehner SP, Heinrich M, Bork PM, Vogt M, Ratter F, Lehmann V, Schulze-Osthoff K, Dröge W and Schmitz ML. . 1998 J. Biol. Chem. 273: 1288–1297.

  • Hehner SP, Hofmann TG, Droge W and Schmitz ML. . 1999 J. Immunol. 163: 5617–5623.

  • Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C and Strauss M. . 1999 Mol. Cell Biol. 19: 2690–2698.

  • Jiang F, Moch H, Richter J, Egenter C, Gasser T, Bubendorf L, Gschwind R, Sauter G and Mihatsch MJ. . 1998 J. Pathol. 185: 382–388.

  • Jones PL, Ping D and Boss JM. . 1997 Mol. Cell Biol. 17: 6970–6981.

  • Kelleher DJ and Gilmore R. . 1997 Proc. Natl. Acad Sci. USA 94: 4994–4999.

  • Kumar A, Dhawan S, Hardegen NJ and Aggarwal BB. . 1998 Biochem. Pharmacol. 55: 775–783.

  • Kumar R, Mandal M, Lipton A, Harvey H and Thompson CB. . 1996 Clin. Cancer Res. 2: 1215–1219.

  • Lee HH, Dadgostar H, Cheng Q, Shu J and Cheng G. . 1999 Proc. Natl. Acad Sci. USA 96: 9136–9141.

  • Legrand O, Simonin G, Perrot J-Y, Zittoun R and Marie J-P. . 1998 Blood 91: 4480–4488.

  • Levkau B, Herren B, Koyama H, Ross R and Raines EW. . 1998 J. Exp. Med. 187: 579–586.

  • Levkau B, Scatena M, Giachelli CM, Ross R and Raines EW. . 1999 Nature Cell. Biol. 1: 227–233.

  • Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC. . 1998 Nature 396: 580–584.

  • Lin ZP, Boller YC, Amer SM, Russell RL, Pacelli KA, Patierno SR and Kennedy KA. . 1998 Cancer Res. 58: 3059–3065.

  • Ling YH, Tornos C and Perez-Soler R. . 1998 J. Biol. Chem. 273: 18984–18991.

  • Liotta LA, Steeg PS and Stetler-Stevenson WG. . 1991 Cell 64: 327–336.

  • Lyss G, Knorre A, Schmidt TJ, Pahl HL and Merfort I. . 1998 J. Biol. Chem. 273: 33508–33516.

  • Manna SK, Zhang HJ, Yan T, Oberley LW and Aggarwal BB. . 1998 J. Biol. Chem. 273: 13245–13254.

  • Miller AD and Rosman GJ. . 1989 Biotechniques 7: 980–982, 984–986, 989–990.

  • Miyake H, Nelson C, Rennie PS and Gleave ME. . 2000 Cancer Res. 60: 170–176.

  • Murphy JJ, Heptinstall S and Mitchell JR. . 1988 Lancet 2: 189–192.

  • Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet Jr RJ and Sledge Jr GW. . 1997 Mol. Cell. Biol. 17: 3629–3639.

  • Newton TR, Patel NM, Bhat-Nakshatri P, Stauss CR, Goulet Jr RJ and Nakshatri H. . 1999 J. Biol. Chem. 274: 18827–18835.

  • Oberley TD and Oberley LW. . 1997 Histol. Histopathol. 12: 525–535.

  • Panvichian R, Orth K, Day ML, Day KC, Pilat MJ and Pienta KJ. . 1998 Cancer Res. 58: 4667–4672.

  • Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T and Gerritsen ME. . 1997 J. Biol. Chem. 272: 21096–21103.

  • Price JE, Polyzos A, Zhang RD and Daniels LM. . 1990 Cancer Res. 50: 717–721.

  • Reuther JY, Reuther GW, Cortez D, Pendergast AM and Baldwin Jr AS. . 1998 Genes Dev. 12: 968–981.

  • Shattuck-Brandt RL and Richmond A. . 1997 Cancer Res. 57: 3032–3039.

  • Shen S-C, Huang T-S, Jee S-H and Kuo M-L. . 1998 Cell Growth Differ. 9: 23–29.

  • Sommers CL, Byers SW, Thompson EW, Torri JA and Gelmann EP. . 1994 Breast Cancer Res. Treat. 31: 325–335.

  • Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM and Sonenshein GE. . 1997 J. Clin. Invest. 100: 2952–2960.

  • Thornberry NA and Lazebnik Y. . 1998 Science 281: 1312–1316.

  • Torres K and Horwitz SB. . 1998 Cancer Res. 58: 3620–3626.

  • Van Antwerp DJ, Martin SJ, Kafri T, Green DR and Verma IM. . 1996 Science 274: 787–789.

  • Wang CY, Cusack Jr JC, Liu R and Baldwin Jr AS. . 1999a Nat. Med. 5: 412–417.

  • Wang CY, Guttridge DC, Mayo MW and Baldwin Jr AS. . 1999b Mol. Cell. Biol. 19: 5923–5929.

  • Wang CY, Mayo MW and Baldwin Jr AS. . 1996 Science 274: 784–778.

  • Wang CY, Mayo MW, Korneluk RG, Goeddel DV and Baldwin Jr AS. . 1998 Science 281: 1680–1683.

  • Xiang J, Chao DT and Korsmeyer SJ. . 1996 Proc. Natl. Acad. Sci. USA 93: 14559–14563.

  • Yang F, de Villiers WJ, McClain CJ and Varilek GW. . 1998 J. Nutr. 128: 2334–2340.

  • Yin MJ, Yamamoto Y and Gaynor RB. . 1998 Nature 396: 77–80.

  • Zandi E and Karin M. . 1999 Mol. Cell. Biol. 19: 4547–4551.

  • Zong W-X, Edelstein LC, Chen C, Bash J and Gélinas C. . 1999 Genes Dev. 13: 382–387.

Download references

Acknowledgements

We thank Drs D Baltimore, K Cornetta, A Hoffmann, LW Oberley and K Orth for various reagents. We also thank I Dunn and C Stauss for technical assistance and R Campbell for critical reading of the manuscript. This work is supported by the grants from Catherine Peachy Fund, Inc., Charles E Culpeper Foundation and Phi Beta Psi Sorority (to H Nakshatri).

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patel, N., Nozaki, S., Shortle, N. et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide. Oncogene 19, 4159–4169 (2000). https://doi.org/10.1038/sj.onc.1203768

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203768

Keywords

This article is cited by

Search

Quick links